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The risk of infective endocarditis in the 21st centuryNalini M. Rajamannan*Department of Molecular Biology and Biochemistry, Mayo Clinic, Mayo College of Medicine, Rochester, MN, USAInfective endocarditis (IE) for decades has been an elusive and
fatal disease without proper recognition and early treatment.
In the past half century, diagnostic imaging, especially in
echocardiography, the possibility of antibiotic therapy and
cardiac surgery during the active infectious process has
played a critical role in themanagement of this disease. In the
19th century, William Osler defined the disease as possible to
treat this disease, and now in the 21st century, endocarditis is
a clinical definable and treatable disease.
Prevention strategies have not lowered the incidence of this
life-threatening disease.1e4 These studies provide the basis for
recent guidelines from the ESC/AHA/ACC,5,6 to provide a strin-
gent approach towards prevention strategies. Despite im-
provements in the diagnostic and therapeutic strategies, the
fatality rate due to IE has not significantly decreased since the
end of the 1970s. The changing epidemiology related to this
disease contributes to the ongoing elusiveness of endocarditis.
Series of case reports published in this issue of IndianHeart
Journal demonstrate the complexity of this disease, the most
frequent causativeagentsnowtend tobeaggressivepathogens
such as staphylococci, resistant-enterococci, or fungi.7,8,9 In
this series of reports there are the usual aggressive pathogens
and also the new genus Granulicatella, as Granulicatella adiacens
a gastrointestinal (GI) flora causing endocarditis in the patient
with rheumatic mitral valve disease. The challenge in the 21st
century is stringent criteria for prophylaxis, the aggressive
pathogens, antibiotic resistance and the growing number of
medical devices implanted in the heart.
The case report of endocarditis late in the course of an
Amplatzer implantation highlights the need for vigilance in
the device patient population. The current prophylaxis
guidelines recommend 6 months until re-endothelization of
the device is complete. However, in this case the patient’s
device was implanted years prior to the diagnosis of the* Mayo Clinic, Department of Biochemistry and Molecular Biology, 16
States.
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highlights again the risk for this type of latent infection in
patients with device implantations. A recent case report from
Turkey illustrates the low, but persistent risk of endocarditis
in patients with ICD-pacemaker implants.10 As the technology
develops including closure devices, pacemaker-ICD and
TAVR, the possibility for device related infections is real and
there is a need for high suspicion in patients with fever,
sepsis, or other clinical features of endocarditis. These pa-
tients need to be screened with transthoracic echocardiogram
(TTE) and if negative and suspicion is high, then trans-
esophageal echocardiogram (TEE) should be performed.
The risk of this disease in the 21st century is dependent on
clinical acumen including the identification of patients at risk
i.e. devices, congenital heart lesions, underlying native valve
disease including rheumatic heart disease, calcific aortic ste-
nosis and mitral valve prolapse, IV drug abuse, and recent
dental/GI/GU manipulation. The clinical symptoms of fever,
anemia, splenomegaly, Osler nodes and Janeway lesions,
although not seen in early clinical presentations, are still the
mainstay of the clinical exam for identifying this disease.
Diagnostic imaging first using TTE is the cornerstone for
this disease classification. Surveillance blood cultures before,
during and after therapy, and follow-up echo is standard.
Finally, if the TTE is negative, but clinical suspicion is high
then TEE is the gold standard for the diagnosis of this disease.
Table 1, indicates the devices which are emerging as the po-
tential for endocarditis. Clinical suspicion for patients with
these devices that present with fever, sepsis and/or non-
specific flu like symptoms must alert the physician to the
possibility of endocarditis.
In the 21st century, efforts should be made to develop new
strategies at each stepof IEmanagement to reduce the residual
causes of IE-related deaths. The possibility of developing new01 Guggenheim, 200 First Street SW, Rochester, MN 55905, United
ty of India. All rights reserved.
Table 1 e Medical devices at risk for infective
endocarditis.
Medical device therapy: risk factors for endocarditis
Prosthetic heart valves
Annuloplasty rings
TAVR
Mitral valve clips
Pacemaker
ICD
Amplatzer closure device
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epidemiologic risk factors for patients at risk are also studies
under intense investigation across the world. Currently, the
challenges in IE management include (i) cost-effective mea-
sures of prevention, (ii) improvement of diagnostic strategies
to reduce the delays for the initiation of the appropriate
treatment, (iii) andbetter identificationof patientswho require
close monitoring and urgent surgery.11r e f e r e n c e s
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